BACKGROUND Pancreatic cancer(PC)is a leading cause of cancer related mortality worldwide,with poor survival due to late diagnosis.Currently,biomarkers have limited use in early diagnosis of PC.Macrophage inhibitory cy...BACKGROUND Pancreatic cancer(PC)is a leading cause of cancer related mortality worldwide,with poor survival due to late diagnosis.Currently,biomarkers have limited use in early diagnosis of PC.Macrophage inhibitory cytokine-1 or growth differentiation factor-15(MIC-1/GDF15)has been implicated as a potential serum biomarker in PC and other malignancies.AIM To determine the role of MIC-1/GDF15 in detecting pre-malignant pancreatic lesions and neoplastic tumours in an asymptomatic high-risk cohort part of Australian Pancreatic Cancer Screening Program.METHODS A feasibility prospective single centre cohort study was performed.Participants recruited for yearly surveillance with endoscopic ultrasound(EUS)had serial fasting blood samples collected before EUS for MIC-1/GDF15,C-reactive protein and carbohydrate antigen 19-9.Patients were stratified into five groups based on EUS findings:Normal;pancreatic cysts,branch-duct intraductal papillary mucinous neoplasm;diffuse non-specific abnormalities;and neoplastic tumours.MIC-1/GDF15 serum levels were quantified using ELISA.Participants in whom EUS demonstrated abnormalities but not malignancy were closely followed up with magnetic resonance imaging(MRI)or computed tomography.RESULTS One hundred twenty participants were prospectively recruited from 2011-2018.Forty-seven participants(39.2%)had an abnormal EUS and five participants(4.2%)were diagnosed with neoplastic tumours,three by EUS(two pancreatic and one liver)and two by MRI/computed tomography(breast cancer,bladder cancer),which were performed for follow up of abnormal EUS.Baseline serum MIC-1/GDF15 was a significant predictor of neoplastic tumours on receiver operator characteristic curve analysis[area under curve(AUC)=0.814,P=0.023].Baseline serum MIC-1/GDF15 had moderate predictive capacity for branch-duct intraductal papillary mucinous neoplasm(AUC=0.644)and neoplastic tumours noted on EUS(AUC=0.793),however this was not significant(P=0.188 and 0.081 respectively).Serial serum MIC-1/GDF15 did not demonstrate a significant percentage change between a normal and abnormal EUS(P=0.213).Median baseline MIC-1/GDF15 was greater in those with neoplastic tumours(Median=1039.6,interquartile range=727.0-1977.7)compared to those diagnosed with a benign lesion(Median=570.1,interquartile range=460.7-865.2)on EUS and MRI(P=0.012).CONCLUSION In this pilot study MIC-1/GDF15 has predictive capacity for neoplastic tumours in asymptomatic individuals with a genetic predisposition for PC.Further imagining may be warranted in patients with abnormal EUS and raised serum MIC-1/GDF15.Larger multicentric prospective studies are required to further define the role of MIC-1/GDF15 as a serological biomarker in pre-malignant pancreatic lesions and neoplastic tumours.展开更多
Objective: The aim of this study was to explore the correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer. Methods: A total of 361 patients with grades I-I...Objective: The aim of this study was to explore the correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer. Methods: A total of 361 patients with grades I-III breast cancer had been followed up from January 2001 to February 2011. Serumal TPS level was measured by enzyme-linked immunosorbent assays (ELISA). Univariate and multivariate analyses were used to investigate associations between pretreatment TPS level and clinicopathological parameters and patient outcomes. Results: First, at the univariate analysis, the expression of TPS was related with some clinicopathological traditional prognostic factors such as tumor size (P = 0.030), histologic grade (P = 0.001) and lymph node status (P = 0.008). Second, overall survival were significantly shorter among patients with elevated pretreatment serum TPS (P = 0.038). However, finally, multivariate Cox regression indicated that the level of pretreatment serum TPS was not an independent prognostic parameter for overall survival in primarily breast cancer patients (P > 0.05). Conclusion: The expression of pretreatment serum TPS is closely correlated with clinicopathology parameters and overall survival of patients with primarily breast cancer, but its level has no independent prognostic value.展开更多
目的:探讨昆明鼠的遗传变异鼠-昆明-无毛(kun ming hairless,KM-HL)鼠对肿瘤细胞的几项生理指标与其他小鼠的区别,为将KM-HL鼠作为肿瘤实验模型用鼠提供理论依据。方法:用TNF-αELISA酶免试剂盒测试KM-HL鼠血清的肿瘤坏死因子(tumornecr...目的:探讨昆明鼠的遗传变异鼠-昆明-无毛(kun ming hairless,KM-HL)鼠对肿瘤细胞的几项生理指标与其他小鼠的区别,为将KM-HL鼠作为肿瘤实验模型用鼠提供理论依据。方法:用TNF-αELISA酶免试剂盒测试KM-HL鼠血清的肿瘤坏死因子(tumornecrosis factor,TNF);将KM-HL鼠接种白血病瘤株(L1210)后,测定TNF-α并计算脾系数、胸腺系数等生理指标;用IL-2ELISA酶免试剂盒测试KM-HL鼠血清的白细胞介素2(interleukin,IL-2);以上两种酶免试剂盒测试方法均用酶标仪在450nm处测定OD值;将KM-HL、KM(昆明种)及ICR鼠接种肝癌H22肿瘤细胞,10d后取肿瘤、肝脏、脾脏及胸腺称质量,计算脾系数和胸腺系数。结果:正常KM-HL鼠的TNF-α为0.144±0.017,比ICR鼠的0.170±0.04低;正常KM-HL鼠接种L1210后血清中的TNF-α为0.176±0.028,比空白KM-HL鼠的0.144±0.017高,P<0.05。KM-HL鼠IL-2为0.137±0.025,与ICR鼠的0.155±0.077基本相似,差异无统计学意义。在肝癌H22肿瘤模型实验中,KM-HL鼠的肿瘤[(2.966±0.94)g]比ICR鼠[(1.262±0.61)g]的肿瘤生长快,差异有统计学意义,P<0.01;KM-HL鼠[(10.461±2.69)mg/g]比KM鼠[(14.959±4.154)mg/g]、ICR鼠[(18.826±4.28)mg/g]的脾系数小,KM-HL鼠[(1.212±0.49)mg/g]比KM鼠[(3.315±0.901)mg/g]、ICR鼠[(2.914±1.28)mg/g]的胸腺系数也小,差异有统计学意义,P值均<0.01。结论:KM-HL鼠对于肿瘤细胞具有易感性,且肿瘤生长均一性好易统计,适合作为肿瘤实验模型用鼠用于抗肿瘤药物的筛选。展开更多
目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型...目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。展开更多
基金Pancare Foundation for their ongoing support and providing funding for the coordinator positionGarvan Institute of Medical Research for their support and ongoing collaboration.
文摘BACKGROUND Pancreatic cancer(PC)is a leading cause of cancer related mortality worldwide,with poor survival due to late diagnosis.Currently,biomarkers have limited use in early diagnosis of PC.Macrophage inhibitory cytokine-1 or growth differentiation factor-15(MIC-1/GDF15)has been implicated as a potential serum biomarker in PC and other malignancies.AIM To determine the role of MIC-1/GDF15 in detecting pre-malignant pancreatic lesions and neoplastic tumours in an asymptomatic high-risk cohort part of Australian Pancreatic Cancer Screening Program.METHODS A feasibility prospective single centre cohort study was performed.Participants recruited for yearly surveillance with endoscopic ultrasound(EUS)had serial fasting blood samples collected before EUS for MIC-1/GDF15,C-reactive protein and carbohydrate antigen 19-9.Patients were stratified into five groups based on EUS findings:Normal;pancreatic cysts,branch-duct intraductal papillary mucinous neoplasm;diffuse non-specific abnormalities;and neoplastic tumours.MIC-1/GDF15 serum levels were quantified using ELISA.Participants in whom EUS demonstrated abnormalities but not malignancy were closely followed up with magnetic resonance imaging(MRI)or computed tomography.RESULTS One hundred twenty participants were prospectively recruited from 2011-2018.Forty-seven participants(39.2%)had an abnormal EUS and five participants(4.2%)were diagnosed with neoplastic tumours,three by EUS(two pancreatic and one liver)and two by MRI/computed tomography(breast cancer,bladder cancer),which were performed for follow up of abnormal EUS.Baseline serum MIC-1/GDF15 was a significant predictor of neoplastic tumours on receiver operator characteristic curve analysis[area under curve(AUC)=0.814,P=0.023].Baseline serum MIC-1/GDF15 had moderate predictive capacity for branch-duct intraductal papillary mucinous neoplasm(AUC=0.644)and neoplastic tumours noted on EUS(AUC=0.793),however this was not significant(P=0.188 and 0.081 respectively).Serial serum MIC-1/GDF15 did not demonstrate a significant percentage change between a normal and abnormal EUS(P=0.213).Median baseline MIC-1/GDF15 was greater in those with neoplastic tumours(Median=1039.6,interquartile range=727.0-1977.7)compared to those diagnosed with a benign lesion(Median=570.1,interquartile range=460.7-865.2)on EUS and MRI(P=0.012).CONCLUSION In this pilot study MIC-1/GDF15 has predictive capacity for neoplastic tumours in asymptomatic individuals with a genetic predisposition for PC.Further imagining may be warranted in patients with abnormal EUS and raised serum MIC-1/GDF15.Larger multicentric prospective studies are required to further define the role of MIC-1/GDF15 as a serological biomarker in pre-malignant pancreatic lesions and neoplastic tumours.
基金Supported by a grant from the Youth Research of Health Department of Fujian Province
文摘Objective: The aim of this study was to explore the correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer. Methods: A total of 361 patients with grades I-III breast cancer had been followed up from January 2001 to February 2011. Serumal TPS level was measured by enzyme-linked immunosorbent assays (ELISA). Univariate and multivariate analyses were used to investigate associations between pretreatment TPS level and clinicopathological parameters and patient outcomes. Results: First, at the univariate analysis, the expression of TPS was related with some clinicopathological traditional prognostic factors such as tumor size (P = 0.030), histologic grade (P = 0.001) and lymph node status (P = 0.008). Second, overall survival were significantly shorter among patients with elevated pretreatment serum TPS (P = 0.038). However, finally, multivariate Cox regression indicated that the level of pretreatment serum TPS was not an independent prognostic parameter for overall survival in primarily breast cancer patients (P > 0.05). Conclusion: The expression of pretreatment serum TPS is closely correlated with clinicopathology parameters and overall survival of patients with primarily breast cancer, but its level has no independent prognostic value.
文摘目的:探讨昆明鼠的遗传变异鼠-昆明-无毛(kun ming hairless,KM-HL)鼠对肿瘤细胞的几项生理指标与其他小鼠的区别,为将KM-HL鼠作为肿瘤实验模型用鼠提供理论依据。方法:用TNF-αELISA酶免试剂盒测试KM-HL鼠血清的肿瘤坏死因子(tumornecrosis factor,TNF);将KM-HL鼠接种白血病瘤株(L1210)后,测定TNF-α并计算脾系数、胸腺系数等生理指标;用IL-2ELISA酶免试剂盒测试KM-HL鼠血清的白细胞介素2(interleukin,IL-2);以上两种酶免试剂盒测试方法均用酶标仪在450nm处测定OD值;将KM-HL、KM(昆明种)及ICR鼠接种肝癌H22肿瘤细胞,10d后取肿瘤、肝脏、脾脏及胸腺称质量,计算脾系数和胸腺系数。结果:正常KM-HL鼠的TNF-α为0.144±0.017,比ICR鼠的0.170±0.04低;正常KM-HL鼠接种L1210后血清中的TNF-α为0.176±0.028,比空白KM-HL鼠的0.144±0.017高,P<0.05。KM-HL鼠IL-2为0.137±0.025,与ICR鼠的0.155±0.077基本相似,差异无统计学意义。在肝癌H22肿瘤模型实验中,KM-HL鼠的肿瘤[(2.966±0.94)g]比ICR鼠[(1.262±0.61)g]的肿瘤生长快,差异有统计学意义,P<0.01;KM-HL鼠[(10.461±2.69)mg/g]比KM鼠[(14.959±4.154)mg/g]、ICR鼠[(18.826±4.28)mg/g]的脾系数小,KM-HL鼠[(1.212±0.49)mg/g]比KM鼠[(3.315±0.901)mg/g]、ICR鼠[(2.914±1.28)mg/g]的胸腺系数也小,差异有统计学意义,P值均<0.01。结论:KM-HL鼠对于肿瘤细胞具有易感性,且肿瘤生长均一性好易统计,适合作为肿瘤实验模型用鼠用于抗肿瘤药物的筛选。
文摘目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。
